Genome-wide association study of survival in patients with pancreatic adenocarcinoma

Gut

Volumn 63, Issue 1, 2014, Pages 152-160

  Wu, Chen ^a,b   Kraft, Peter ^a   Stolzenberg Solomon, Rachael ^c   Steplowski, Emily ^d   Brotzman, Michelle ^e   Xu, Mousheng ^a   Mudgal, Poorva ^a   Amundadottir, Laufey ^c   Arslan, Alan A ^f,g   Bueno De Mesquita, H Bas ^h,i   Gross, Myron ^j   Helzlsouer, Kathy ^k,l   Jacobs, Eric J ^m   Kooperberg, Charles ⁿ   Petersen, Gloria M ^o   Zheng, Wei ^p   Albanes, Demetrius ^c   Boutron Ruault, Marie Christine ^q   Buring, Julie E ^r,s   Canzian, Federico ^t   Cao, Guangwen ^u   Duell, Eric J ^v   Elena, Joanne W ^c   Gaziano, J Michael ^r,w   Giovannucci, Edward L ^a,r   Hallmans, Goran ^x   Hutchinson, Amy ^y   Hunter, David J ^a   Jenab, Mazda ^z   Jiang, Guoliang ^aa   Khaw, Kay Tee ^ab   LaCroix, Andrea ⁿ   Li, Zhaoshen ^u   Mendelsohn, Julie B ^c   Panico, Salvatore ^ac   Patel, Alpa V ^m   Qian, Zhi Rong ^ad   Riboli, Elio ^ae   Sesso, Howard ^r   Shen, Hongbing ^af   Shu, Xiao Ou ^p   Tjonneland, Anne ^ag   Tobias, Geoffrey S ^c   Trichopoulos, Dimitrios ^a,ah   Virtamo, Jarmo ^ai   Visvanathan, Kala ^aj   Wactawski Wende, Jean ^ak   Wang, Chengfeng ^b   Yu, Kai ^c   Zeleniuch Jacquotte, Anne ^f,g   Chanock, Stephen ^c   Hoover, Robert ^c   Hartge, Patricia ^c   Fuchs, Charles S ^r,ad   Lin, Dongxin ^b   Wolpin, Brian M ^r,ad   more..

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CANCER HOSPITAL   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e WESTAT   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^k MERCY MEDICAL CENTER   (United States)

^l JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^m AMERICAN CANCER SOCIETY   (United States)

ⁿ Fred Hutchinson Cancer Research Center   (United States)

^o MAYO CLINIC   (United States)

^p VANDERBILT INGRAM CANCER CENTER   (United States)

^q INSERM   (France)

^r BRIGHAM AND WOMEN S HOSPITAL   (United States)

^s HARVARD MEDICAL SCHOOL   (United States)

^t GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^u SECOND MILITARY MEDICAL UNIVERSITY   (China)

^v CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^w VETERANS AFFAIRS MEDICAL CENTER   (United States)

^x UMEÅ UNIVERSITY   (Sweden)

^y SAIC FREDERICK INC   (United States)

^z INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^aa FUDAN UNIVERSITY   (China)

^ab UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ac UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^ad DANA FARBER CANCER INSTITUTE   (United States)

^ae IMPERIAL COLLEGE LONDON   (United Kingdom)

^af NANJING MEDICAL UNIVERSITY   (China)

^ag DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^ah BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^ai NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^aj JOHNS HOPKINS UNIVERSITY   (United States)

^ak UNIVERSITY AT BUFFALO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER SURVIVAL; CAUSE OF DEATH; CHINA; CHROMOSOME 11P; CHROMOSOME 18P; CHROMOSOME 1P; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERM LINE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POPULATION RESEARCH; PRIORITY JOURNAL; SET BINDING FACTOR 2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

CANCER GENETICS; MOLECULAR EPIDEMIOLOGY; PANCREATIC CANCER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MODELS, GENETIC; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84889680673     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303477     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 (Internet). Lyon, France: International Agency for Research on Cancer, 2010. http://globocan.iarc.fr (accessed 30 Mar 2012).
3. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
4. Azzato EM, Tyrer J, Fasching PA, et al. Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst 2010;102:650-62.
5. Wu C, Xu B, Yuan P, et al. Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients. Cancer Res 2010;70:9721-9.
6. Wu X, Ye Y, Rosell R, et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 2011;103:817-25.
7. Olson P, Hanahan D. Cancer. Breaching the cancer fortress. Science 2009;324:1400-1.
8. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-16.
9. Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011;19:429-31.
10. Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut 2011;60:861-8.
11. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
12. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:418-29.
13. Asomaning K, Reid AE, Zhou W, et al. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res 2008;14:4010-15.
14. Couch FJ, Wang X, Bamlet WR, et al. Association of mitotic regulation pathway polymorphisms with pancreatic cancer risk and outcome. Cancer Epidemiol Biomarkers Prev 2010;19:251-7.
15. Dong X, Javle M, Hess KR, et al. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology 2010;139:464-73, 473 e461-463.
16. Li D, Liu H, Jiao L, et al. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res 2006;66:3323-30.
17. Okazaki T, Javle M, Tanaka M, et al. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010;16:320-9.
18. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009;41:986-90.
19. Petersen GM, Amundadottir L, Fuchs CS, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010;42:224-8.
20. Wu C, Miao X, Huang L, et al. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet 2012;44:62-6.
21. Wolpin BM, Kraft P, Gross M, et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 2010;70:1015-23.
22. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook. New York: Springer, 2002.
23. Young JLJ, Roffers SD, Ries LAG, et al. SEER Summary Staging Manual - 2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute, NIH Pub. No. 01-4969, 2001.
24. Dixon AL, Liang L, Moffatt MF, et al. A genome-wide association study of global gene expression. Nat Genet 2007;39:1202-7. (Pubitemid 47482680)
25. Innocenti F, Owzar K, Cox NL, et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 2012;18:577-84.
26. Panagiotou OA, Ioannidis JP. What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. Int J Epidemiol 2012;41:273-86.
27. Kirfel J, Senderek J, Moser M, et al. Cloning, expression and characterization of the murine orthologue of SBF2, the gene mutated in Charcot-Marie-Tooth disease type 4B2. Gene Expr Patterns 2006;6:978-84. (Pubitemid 44309452)
28. Chasman DI, Pare G, Mora S, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet 2009;5:e1000730.
29. Ying H, Elpek KG, Vinjamoori A, et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov 2011;1:158-69.
30. Berger P, Tersar K, Ballmer-Hofer K, et al. The CMT4B disease-causing proteins MTMR2 and MTMR13/SBF2 regulate AKT signalling. J Cell Mol Med 2011;15:307-15.
31. Berger P, Berger I, Schaffitzel C, et al. Multi-level regulation of myotubularin-related protein-2 phosphatase activity by myotubularin-related protein-13/set-binding factor-2. Hum Mol Genet 2006;15:569-79. (Pubitemid 43205422)
32. Bolino A, Muglia M, Conforti FL, et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet 2000;25:17-19. (Pubitemid 30257029)
33. Senderek J, Bergmann C, Weber S, et al. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet 2003;12:349-56. (Pubitemid 36204431)
34. Azzedine H, Bolino A, Taieb T, et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet 2003;72:1141-53. (Pubitemid 36530002)
35. Tersar K, Boentert M, Berger P, et al. Mtmr13/Sbf2-deficient mice: an animal model for CMT4B2. Hum Mol Genet 2007;16:2991-3001. (Pubitemid 350131317)
36. Robinson FL, Niesman IR, Beiswenger KK, et al. Loss of the inactive myotubularin-related phosphatase Mtmr13 leads to a Charcot-Marie-Tooth 4B2-like peripheral neuropathy in mice. Proc Natl Acad Sci U S A 2008;105:4916-21. (Pubitemid 351753846)
37. Robinson FL, Dixon JE. Myotubularin phosphatases: policing 3-phosphoinositides. Trends Cell Biol 2006;16:403-12. (Pubitemid 44160552)
38. Lei SF, Tan LJ, Liu XG, et al. Genome-wide association study identifies two novel loci containing FLNB and SBF2 genes underlying stature variation. Hum Mol Genet 2009;18:1661-9.
39. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009;301:2553-62.
40. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
41. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294:2872-8. (Pubitemid 41785868)
42. Michaud DS, Giovannucci E, Willett WC, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001;286:921-9. (Pubitemid 33010338)
43. Chung CC, Chanock SJ. Current status of genome-wide association studies in cancer. Hum Genet 2011;130:59-78.
44. Haiman CA, Chen GK, Blot WJ, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet 2011;7:e1001387.